girentuximab

girentuximab

A chimeric IgG1 monoclonal antibody that targets carbonic anhydrase IX. Phase-1 and -2 studies of girentuximab plus low-dose IFN-alpha in patients with progressive metastatic renal cell carcinoma indicated that the combination therapy was safe, well tolerated and demonstrated clinical benefit in the patient population.
References in periodicals archive ?
Van Oostenbrugge, "Phase 2 study of lutetium 177-labeled anticarbonic anhydrase IX monoclonal antibody girentuximab in patients with advanced renal cell carcinoma," European Urology, vol.
Girentuximab is an mAb that specifically recognizes carbonic anhydrase IX overexpressed in renal cell carcinoma (Table 1).
Van Oostenbrugge et al., "Phase 2 Study of Lutetium 177-Labeled Anti-Carbonic Anhydrase IX Monoclonal Antibody Girentuximab in Patients with Advanced Renal Cell Carcinoma," European Urology, vol.
WILEX's manufacturing partner Avid Bioservices Inc, a unit of Peregrine Pharmaceuticals (NASDAQ:PPHM), has completed the production run of the third consecutive consistency lot for process validation of the naked antibody Girentuximab.